無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Digital Landscape:多発性硬化症(MS)

Digital Landscape: Multiple Sclerosis

発行 GlobalData 商品コード 692902
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.67円で換算しております。
Back to Top
Digital Landscape:多発性硬化症(MS) Digital Landscape: Multiple Sclerosis
出版日: 2018年08月27日 ページ情報: 英文 164 Pages
概要

当レポートでは、米国およびEUCAN諸国(EU5カ国・カナダ)の製薬企業がデジタル環境(ブランドウェブサイト、非ブランド/疾患啓発ウェブサイト、モバイルアプリ、ソーシャルメディア)で多発性硬化症患者および医療従事者を対象に展開している取り組みについて詳細に調査し、主要企業の動向の比較、新たなキャンペーン活動の機会の特定、デジタルヘルスを形作るトレンドの評価、患者および医師のオンライン利用実態などについてまとめています。

対象企業

Biogen、Sanofi、Genzyme、Teva、Merck KGaA、EMD Serono、Roche、Genentech、Novartis、Bayer、Mylan、Sandoz、Almirall、Celgene

目次

  • エグゼクティブサマリー
  • 近年の動向
  • 情勢と分析
  • 米国:多発性硬化症患者を対象とした取り組み
  • 米国:医療従事者を対象とした取り組み
  • EUCAN諸国:多発性硬化症患者を対象とした取り組み
  • EUCAN諸国:医療従事者を対象とした取り組み
  • 調査手法
目次
Product Code: GDHC038SP

"Digital Landscape: Multiple Sclerosis", report analyzes digital activities undertaken by Pharma industry in support of disease-modifying therapies for Multiple Sclerosis (MS).

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights

  • US Patients: Overall, digital pharma support is strong for MS patients in the US; good quality branded and unbranded resources detected, particularly from Biogen, Teva and Sanofi Genzyme. Patients are well supported by social media, with branded Facebook pages from Teva, Novartis and EMD Serono the most successful. Less mobile app activity seen, with top offerings from branded treatment trackers, with Bayer's new app achieving early success.
  • US HCPs: There is little support for HCPs in the MS space beyond branded, with Genzyme, Biogen, and Teva offering the best branded resources. The pharma-sponsored unbranded and mobile app landscapes are sparse, and opportunities may exist to develop or sponsor content with trusted non-pharma organizations. HCP-directed social media activity restricted to posts from corporate accounts, with examples of HCP-specific accounts seen in other diseases.
  • EUCAN Patients: MS patients in EUCAN are well supported by pharma overall, particularly those in Germany. Support is weakest in the UK and Canada. Best branded support seen from Sanofi Genzyme, Teva and Merck KGaA, with most brand activity related to patient support programs. Pharma provides strong unbranded support but no multi-country, local-language campaigns, with the majority of sites are supported by social media. Pharma-sponsored mobile app landscape is strong, particularly from Novartis, with common features including disease tracking and reminders.
  • EUCAN HCPs: Limited HCP support provided by pharma in MS beyond brand sites. Merck KGaA and Sanofi Genzyme offer the best branded support, with a number of sites detected across EUCAN. The unbranded and mobile app landscapes are undeveloped, and like the US, partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.
  • Companies Mentioned: Biogen, Sanofi Genzyme, Teva, Merck KGaA / EMD Serono, Roche / Genentech, Novartis, Bayer, Mylan, Sandoz, Almirall, Celgene

Scope

  • This report analyzes digital activities undertaken by Pharma in support of disease-modifying therapies for MS.
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy

  • Our Digital Landscape report provides an analysis of Pharma multichannel activity in the digital MS space, and can assist our Pharma clients derive value in a number of ways:
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in MS
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in MS and beyond, and learn about key patient and physician online activities in MS.

Table of Contents

  • Executive Summary
  • Recent Developments
  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology
Back to Top